Experimental drug aims to mop up remaining cancer cells after standard treatment
NCT ID NCT01258933
Summary
This study tested whether the drug ofatumumab could control chronic lymphocytic leukemia or small lymphocytic lymphoma that remained after patients completed chemotherapy. Participants received up to 20 infusions over two years to target residual cancer cells. The trial was terminated early with only 4 participants enrolled, so results are limited.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.